Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab for Moderate to Severe Scalp Psoriasis
ChiCTR2600130630Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimekizumab in psoriasis, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Scalp Psoriasis Severity Index (SSI) score and lesion response rate (SSI75, SSI90, SSI100) at week 24. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2600130630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130630.